Compare Cytokinetics Inc (CYTK) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Western Union Co — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Western Union Co trades at $6.32 (market cap $1.91B). The key difference: Cytokinetics Inc is far larger — about 4.5× Western Union Co's market cap, and Western Union Co pays a 15.38% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Western Union Co for 95 Days on average.
| CYTK | WU | |
|---|---|---|
Market Cap | $8.50B | $1.91B |
Volume | 2,395,556 | 6,459,194 |
Sector | Health | Financials |
52-Week High | $87.26 | $10.28 |
52-Week Low | $54.76 | $5.90 |
Typical Hold Time | 19 Days | 95 Days |
Enterprise Value | $8.60B | $1.81B |
Dividend Yield | — | 15.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Western Union (WU) trades at $6.33, up 3.09% with bearish technical signals but attractive valuation metrics including a P/E of 4.93 and P/S of 0.48. Recent earnings show mixed performance with two misses in the last three quarters, while the company maintains strong profitability with 9.79% net margin and 43.97% ROE. The $200 million Beyond Efficiency Plan and pending Intermex acquisition represent key strategic initiatives amid declining revenue trends from $4.5B in 2022 to $4.0B projected for 2026.
WU presents a value opportunity with deep valuation discounts but faces significant headwinds including revenue contraction and integration risks from the Intermex acquisition. Analyst sentiment remains cautious with only 12% buy ratings, though the $6.86 consensus target offers 8% upside. The stock's appeal hinges on successful cost-cutting execution and digital transformation amid competitive pressures in money transfer services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
